aTyr Pharma launches Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis, citing positive Phase 1b/2a data

aTYR PHARMA INC

Phase 3 EFZO-FIT will enroll 264 patients; primary endpoint is steroid reduction; secondary endpoints include lung function and symptoms.
Phase 1b/2a data showed dose-dependent improvements; 5.0 mg/kg group had three patients completely taper off steroids.
Efzofitimod demonstrated control of inflammatory biomarkers (IFN-γ, IL-6, IP-10, MCP-1, TNFa) over 24 weeks.
Two higher doses (3.0 and 5.0 mg/kg) improved lung function measures (FVC, DLCO) vs placebo.
Trial expected to initiate Q3 2022; Phase 1b/2a results presented at ATS 2022 conference May 17.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.